Long-term treatment with golimumab for severe uveitis

Elisabetta Miserocchi, Giulio Modorati, Irene Pontikaki, Pier Luigi Meroni, Valeria Gerloni

Research output: Contribution to journalArticle


Purpose: To evaluate the long-term efficacy of golimumab in patients with severe recalcitrant uveitis who had inadequate response to previous biologics. Methods: Retrospective study (13 patients with JIA, 4 with HLA-B27-associated uveitis). Indication for treatment was active uveitis despite biologics. Golimumab dosing was 50mg monthly/subcutaneously. Main outcome measures: uveitis activity, visual acuity improvement, reduction of systemic therapy (corticosteroids/immunosuppressants), adverse events. Results: Of 17 patients (34 affected eyes), response to golimumab was seen in 14 patients; at last visit uveitis was inactive in 12 patients. Three patients were nonresponders. Mean follow-up time on golimumab was 21.9 months. Visual acuity remained stable in 26 eyes, improved in 7, and worsened in 1. Mean systemic prednisolone dose before and after golimumab was 12.5-3.5mg/day. One patient developed pulmonary infection. Conclusions: Golimumab may be a promising new therapeutic option for severe uveitis patients who have not responded to other biologics.

Original languageEnglish
Pages (from-to)90-95
Number of pages6
JournalOcular Immunology and Inflammation
Issue number2
Publication statusPublished - 2014


  • Golimumab
  • HLA-B27; JIA
  • TNF-alpha blockers
  • Uveitis

ASJC Scopus subject areas

  • Ophthalmology
  • Immunology and Allergy
  • Medicine(all)

Fingerprint Dive into the research topics of 'Long-term treatment with golimumab for severe uveitis'. Together they form a unique fingerprint.

  • Cite this